Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312), a Selective S1P1,5 Receptor Modulator, on Cardiac Repolarization: A Thorough QTc (TQT) Study

Trial Profile

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312), a Selective S1P1,5 Receptor Modulator, on Cardiac Repolarization: A Thorough QTc (TQT) Study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Siponimod (Primary) ; Moxifloxacin
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 27 Oct 2015 Results published in the Clinical Therapeutics
    • 29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top